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well as reduces the debilitating burden of walking disability in MS patients. Future
studies are required to investigate the direct cost offsets as a result of treatment
with PR-fampridine.
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OBJECTIVES: To estimate the costs of management of children with structural-
metabolic epilepsy and to determine the cost-driving factors in the selected
population. METHODS: This was a retrospective annual prevalence-based study
that included patients who attended a paediatric neurology clinic in a tertiary
referral centre inMalaysia. The total costs of epilepsymanagementwere estimated
from the provider (i.e., hospital) perspective, using a bottom-up,microcosting anal-
ysis. Medical chart/billing data (i.e., case reports) obtained from the hospital (i.e.,
provider) were collected to determine the resources used. Prices or cost data were
standardised for the year 2010. RESULTS: Themost expensive item in the costs list
was antiepileptic drugs, whereas ultrasound examination represented the cheap-
est item. Hospitalisation and the use of non-antiepileptic drugs were the second
and third most costly items, respectively. The cost of therapeutic drug monitoring
comprised only a small proportion of the total annual expenditure. None of the
demographic variables (i.e., gender, race, and age) significantly impacted the an-
nual cost of epilepsy management. Similarly, child development and seizure type
were also not associatedwith the cost ofmanagement. On the other hand, children
who received polytherapy treatment, therapeutic drug monitoring, or adjuvant
therapy with new antiepileptic drugs represented high-cost groups of patients.
Moreover, the total annual cost of epilepsymanagement positively correlated with
seizure frequency. CONCLUSIONS: This investigation was the first cost analysis
study of epilepsy inMalaysia. The total annual cost ofmanagement for 120 patients
with structural-metabolic epilepsy was RM 202,816 (i.e., RM 1690.13 per patient per
year). The study findings highlight the importance of optimizing seizure control in
reducing the cost of management.
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OBJECTIVES:With the ageing of the population, dementia has emerged as a major
public health and economic burden in industrialized countries. Our study aimed at
evaluating direct health care costs in a population of community-dwelling elderly
patients with treated dementia and at comparing such costs with those among
non-demented elderly.METHODS: A retrospective cohort study was conducted in
the community-dwelling elderly population of Quebec using the RAMQ adminis-
trative claims databases (medical services and prescribed medications) and the
Med-Echo hospital discharge database. Patients aged 66 and over, who received at
least one dispensing for a cholinesterase inhibitor (ChI) (donepezil, rivastigmine, or
galantamine) between January 1, 2000 and December 31, 2009 were included in the
cohort of patients with dementia (n37,138). The date of entry in the cohort (index
date) was the date of first dispensing for a ChI during the study period. The com-
parison cohort included elderly patients with no diagnosis of dementia matched
with a 1:1 ratio on age group, gender, and index date. Economic variables included
direct costs of prescribed medications, medical services, hospitalizations and
institutionalization. RESULTS: Overall, our study showed that, at 1 year follow-up,
total health care costs are higher among patients with dementia than among non-
demented elderly (CAD$8360 compared to CAD$5368). Costs associated with ChI
treatment ($1285) andhospitalization ($1103) accounted for the greatest proportion
of the cost difference between the two populations. Over a five-year period, total
health care costswere $38,200 ( $62,180) in the cohortwith dementia compared to
$19,042 ( $31,346) in non-demented elderly. At this time, costs associateed with
institutionalization also contributed significantly to the difference.
CONCLUSIONS: Dementia is an important socioeconomic burden. Despite the
availability of treatments for dementia and the high death rate over a 5-year period,
costs associated with hospitalization and institutionalization increase exponen-
tially, resulting in a major public health burden.
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OBJECTIVES: Patients with neurological conditions such as multiple sclerosis or
spinal cord injurymay experience urinary incontinence resulting from neurogenic
detrusor overactivity (NDO). In addition to reduced quality of life, uncontrolled
NDO can have pathophysiological consequences including urological disorders
and renal failure. Studies have shown that a substantial proportion ofNDOpatients
are inadequately managed by conservative treatments, which include lifestyle
modifications and oral anticholinergicmedication. Recent clinical trials have dem-
onstrated that botulinum toxin type A injections significantly reduce incontinence
frequency. The objective of this study is to examine the cost reductions following
treatment with botulinum toxin type A in NDO patients, in the context of the
Australian health care system. METHODS: Based on data from two Phase III dou-
ble-blinded randomised placebo-controlled trials in NDO patients, a semi-Markov
model was developed to compare treatment with 200U of botulinum toxin type A
versus best supportive care (BSC: pads, catheters, and the option of anticholin-
ergics). Systematic literature searches and a survey of continence nurse practitio-
ners were conducted to source additional information (eg, natural history or re-
source utilisation of NDO patients). The costs considered in themodel include drug
costs, incontinence-related costs (eg, pads, catheterisation), and downstream
health care costs (eg, bladder augmentation surgery). RESULTS: Over a time hori-
zon of 5-years, compared to BSC, botulinum toxin type A treatment results in a
reduction in cost of incontinence pads ($2,445), catheterisation ($592), and a
modest reduction in general practitioner visits ($141) and the likelihood of un-
dergoing bladder augmentation surgery ($235). CONCLUSIONS: Botulinum toxin
typeA treatment is associatedwith cost reductions inNDOpatients and represents
a viable treatment option for NDO patients who are inadequately managed by oral
anticholinergics, and who may otherwise have to consider invasive surgical inter-
ventions.
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The costs of multiple sclerosis (MS) in China are not well known because of com-
paratively low prevalence rate and treatment complexity. OBJECTIVES: To assess
the treatments and costs of MS in China from social perspective by surveying both
patients and physicians.METHODS:Multi-center, questionnaire-based surveywas
conducted in major cities of China to collect health resource utilization, direct and
indirect costs related to MS. An Excel-based model was developed to estimate the
annual cost of MS in China by combining prevalence rate from systematic litera-
ture review, data from surveys and other published information. The costs ofMS in
China were estimated from patient and physician surveys separately and com-
pared with each other. RESULTS: A total of 110 relapsing-remitting multiple scle-
rosis (RRMS) patients and 5 physicians participated the survey. Patients (12.7% age
30; 55.4% age 30-50; and 31.9% age 50 years old) were assessed by Expanded
Disability Status Scale (EDSS) (36% mild; 51% moderate, and 13% sever). The total
cost from patient survey was USD 18,566 (1 USD 6.56 RMB, 2010-2011) (USD 13,265
direct cost and USD 5301 indirect cost) per person year. Total direct cost from
physician survey was USD 10,307 per year (USD 7,137 for medications). Annually
total cost of MS in China, using prevalence data from an epidemiology study, was
estimated to be USD 331.7 million (USD 245.2 million direct costs and USD 86.5
million indirect costs). CONCLUSIONS: The study shows that MS imposes a consid-
erable burden on Chinese patients, especially during disease diagnosis and relapse
periods. Unlike western countries, few patients in China take Disease Modified
Treatments (DMTs) because of the high out of pocket costs. The indirect costs ofMS
are significant and may increase in the near future, which will exacerbate the
burden on individual patients.
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OBJECTIVES: To evaluate the cost-effectiveness analysis of two Disease-modifying
drugs (DMD) used as first-line treatment of Relapsing Remitting Multiple Sclerosis
(RRMS): interferon IFN-1a IM injection (Avonex®) and IFN -1b SC injection (Be-
taferon®) from IranianMinistry of Health perspective.METHODS:A cost-effective-
ness analysis (CEA) was performed fromMinistry of Health (MoH). The outcome of
interest was number of relapses avoided. Costs were reported in 2011 USD. Costs
and outcomes were discounted at 5%. The time horizon was two years. All uncer-
tainties were tested via one-way sensitivity analyses. RESULTS: Total costs per
patient over the time horizon of a study were estimated at 39923, 47670 and 52045
USD for symptom management, IM IFN-1a and SC IFN-1b, respectively. The
incremental cost per relapse avoided was 25823 and 14965 USD for IM IFN-1a and
SC IFN-1b, respectively, compared with no active treatment (symptom manage-
ment). Results were sensitive to the discount rate, frequency of relapse and cost of
DMDs. CONCLUSIONS: The cost-effectiveness analysis determined that INF-1b
SC (Betaferon® ) was the best strategy of the two immunomodulatory therapies
used to treatment of patients experiencing an relapsing-remitting multiple sclero-
sis (RRMS) and resulted in better outcomes than symptom management alone.
Sensitivity analyses indicated that themodel was sensitive to changes in a number
of key parameters, and thus changes in these key parameters would likely influ-
ence the estimated cost-effectiveness results.
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OBJECTIVES: A post-hoc sub-group analysis provides evidence that lacosamide
when used in conjunction with a non-sodium-channel blocking AED ismore effec-
tive than when used in combination with another sodium-channel blocking AED.
In order to allow patients earlier subsidised access to lacosamide (via the Pharma-
ceutical Benefits Scheme), a cost-effectiveness analysiswas conducted.METHODS:
Three large randomised, placebo controlled trials (SP667, SP754 and SP755) were
meta-analysed. More specifically, the analysis examined lacosamide used in con-
junction with a non-sodium channel AED (the sub-group) vs. lacosamide used in
conjunction with at least one sodium channel AED (the complement group). A deci-
sion tree (TreeAge) economic model reported the “cost per incremental 50% re-
sponder”. Lacosamide was utilised in the compliment group as a proxy for other
(similarly priced) adjunctive AED treatment. RESULTS: The meta-analysis, com-
pared those trial patients meeting the proposed PBS indication (the sub-group) to its
complement. More patients in the subgroup achieved a 50% reduction in seizure
frequency compared to the complement (51.1% vs. 34.7% respectively). Based on the
test of effect modification, there is a statistically meaningful effect modification
within the proposed subgroup (p0.03). The modelled incremental cost effective-
ness ICER, lacosamide (sub-group) costs $3064 per additional patient who achieves
at least a 50% reduction in seizures compared to the compliment. CONCLUSIONS:
A reimbursed listing on the PBS was sought which would limit the use of lacos-
amide to a refractory group and then only in combination with non-sodium AEDs.
Probabilistic sensitivity analysis was undertaken which showed that the PBAC
could be confident in that 68% of the outcomes are below $4000/responder. This
supported the robustness of the ICER. The analysis could have been strengthened
had it been based on a pre-specified analysis (and therefore randomised accord-
ingly), rather than on a post-hoc analysis.
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OBJECTIVES: To evaluate societal and economic benefits of self-administrated in-
jection of sumatriptan succinate compared to hospital-administrated one in the
treatment of acute severemigraine in Japan setting.METHODS:A cost-utility anal-
ysis (cost per QALY gained) by simulatingwith a 5-stateMarkovModel is conducted
from the societal perspective. Parameters incorporated into the model were taken
from literatures and the PMS of subcutaneous sumatriptan carried out in Japan.
Cost components incorporated into the model consist of migraine-related medical
costs, medicines, and transportation costs for traditional health care provider and
emergency room visits, calculating with Japan insurance-based medical fee
scheme for medical techniques and national health insurance price of medicines.
To assess robustness of a base case, univariate sensitivity analyses using tornado
diagram and probabilistic analysis using 10000-time Monte Carlo simulation were
performed. TreeAge Pro 2007 was used for the data analysis. RESULTS: At the base
case, it was deemed that use of self-administrated injection was less costly and
more effectiveness than hospital-administrated one. Univariate analyses revealed
that probability of onset of attack per week was identified as a cost driver. The
probabilistic analysis suggested that if willingness to pay on decision-making in
Japan setting was set at 5,000,000 JPY per QALY gained, approximately 100% of
probabilitywere obtained dominant consequences in a hypothetical cohort. There-
fore, it was demonstrated robustness of the base case analysis, retrospectively.
CONCLUSIONS: Thus, the aforementioned result suggested that the use of self-
administrated injection dominated hospital-administrated one irrespective of a
high initial price of self-administrated injection.
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OBJECTIVES:To evaluate the 10 year utilization trends of antiepileptic drugs (AEDs)
in Iran. METHODS: Annual pharmaceutical sales data were acquired from the
Ministry ofHealth (MOH). To express data, Anatomical Therapeutic Chemical (ATC)
classification and Defined Daily Dose (DDD) as described by WHO collaborating
centre for drug statistics methodology were used. DDD/1000 Inhabitants/Day (DID)
was the main unit for measuring drug sales and N03 was considered as AEDs here.
RESULTS: Between 2000 and 2010, the total consumption of antiepileptic drugs
increased by 49.85%, and reached 8.7 DDD/1000 inhabitants/day in 2010.Within the
studied ten years, the consumption of old AEDs increased by 9.6% (6.37 DDD/1000
inhabitants/d ay in 2010), while in the case of new AEDs the increase was 11432%
(2.37 DDD/1000 inhabitants/day). CONCLUSIONS: A significant shift can be seen in
the consumption of newAEDs. This change is partly due to the improved efficacy of
these drugs compared to the older types and referable to new indications to some
extent.
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OBJECTIVES:Multiple sclerosis (MS) is a costly disease that affects adults. There are
very few studies evaluating the impact of high disease activity (HDA) on costs and
resource use using real world data. This study aims to compare demographics, cost
and resource utilization of MS patients with high and low annual relapses.
METHODS: A retrospective cross-sectional study was done using MarketScan®
commercial claim and Medicare database, 2009. Patients included had at least one
ICD-9 for MS (340.XX), were older than 18 years, and had continuous enrolment for
one year. HDA was defined as having two relapses annually, and relapse was de-
fined according to Chastek 2010 algorithm. Bivariate analysis were conducted to
compare HDA patients and other MS patients on patient characteristics, resource
utilization and costs (chi-square test for categorical variables and t-test for contin-
uous variables). RESULTS: A total of 22,170 patients met the study criteria. 94.58%
(N20,969) had less than two relapses and 5.42% (N1,201) had more than two
relapses in 2009. HDA patients were younger (49 vs. 52 years) and less likely to be
employed (50.54% vs. 56.12%). MS symptoms were more frequent in HDA group
including pain (54.87% vs. 39.55%), balance and coordination problems (24.23% vs.
10.72%) and fatigue (24.06% vs. 12.64%). HDA patients had more all cause and MS-
specific hospitalizations (26.39% vs. 12.59% and 15.24% vs. 1.62%) and ER visits
(39.88% vs.23.39% and 21.15% vs. 7.75%) compared to non-HDApatients. Mean total
cost (excluding DMT drug costs) for the HDA group was US$30,637 compared with
US$14,240 for the non-HDA group. p 0.0001 for all. CONCLUSIONS: Patients with
two or more relapses annually have high resource utilization and are more costly.
Two or more relapse annually seem to be indicative of high disease activity, how-
ever, amore robust algorithm needs to be validated to study such population using
claims database.
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OBJECTIVES: Chronic migraine (CM), defined as headache on at least 15 days per
month, with at least 8 days of migraine, is a sub-type of chronic daily headache
associated with significant quality of life (QoL) impairment. Clinical studies dem-
onstrate that botulinum toxin type A (BTX-A, 155-195U injected at specific head
and neck areas) results in clinically significant improvements in headache symp-
toms and QoL for CM patients. This study was conducted to obtain patient narra-
tives describing how response to BTX-A has benefited them in their daily lives.
METHODS: CM patients undergoing treatment with BTX-A were recruited via a
letter from their neurologist for in-depth interviews. The participants were ten
female chronic migraineurs who had suffered from migraines for 7-35 years, and
had received BTX-A treatment for 6 months to 5 years. RESULTS: For all partici-
pants, CMwas severely debilitating across all aspects of their lives including work/
study, family/personal relationships and social interactions. Some patients re-
ported prior symptoms of depression including suicidal ideation. The participants
had previously trialled numerous acute and prophylactic treatments but had ex-
perienced lack of efficacy, intolerance and rebound headaches from medication
overuse. Following treatment with BTX-A, participants reported reduced fre-
quency, severity and duration ofmigraines and headaches, increased dayswithout
acute medication intake, and improved response to simple analgesics. Personal
benefits included the ability to return to work or study, care for their children,
engage in social activities and take more active roles in the community. Partici-
pants felt that public reimbursement of BTX-A for CM would have a number of
positive outcomes including reduced financial stress of treatment for themselves
and their families, as well as potential cost reductions to the health care system
from decreased use of other medications and less hospitalisations and/or doctor
visits. CONCLUSIONS: CM patients responding to BTX-A prophylaxis report im-
proved symptoms and multiple QoL benefits.
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OBJECTIVES: Many studies as well as clinical experience indicate that moderate-
to-severe psoriasis is an emotionally and socially disabling disease. Themajority of
these studies, however, have been conducted in western countries, including Eu-
rope andNorth America. This study aimed to determine the burdens of psoriasis in
patients with psoriasis living in the Asia Pacific countries.METHODS:A systematic
literature search was conducted to identify evidence published between January
1990 and February 2012 evaluating the disease burdens, quality of life, and epide-
miology of psoriasis in Asia Pacific. RESULTS: Forty-five publications from China,
Hong Kong, India, Malaysia, Singapore, South Korea, and Taiwan were identified.
This literature demonstrated that psoriasis produces substantial impairments in
patients’ quality of life (QOL), and the level of impairment is dependent on the
patients’ disease severity. Across the retrieved literature, severely impaired quality
of life was observed in 19-39% of patients. The Dermatology Life Quality Index
(DLQI), a commonly used instrument to assess skin disease-specific QOL showed a
mean score of 6-20, indicating a moderate to very large effect of psoriasis on QOL.
Patients experienced difficulty in social life, daily activities, and reduced work
productivity. A higher Psoriasis Area and Severity Index (PASI) score (greater dis-
ease severity) was correlated with more impaired QOL. Psoriasis patients also suf-
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